On March 14, 2022 NETRIS Pharma reported that the ANR (Agence Nationale de la Recherche) allocated a 6.6 M€ grant to the RHU DEPGYN project aiming to develop new therapeutic approaches targeting the dependence receptors in gynecological cancers (Press release, Netris Pharma, MAR 14, 2022, View Source [SID1234611181]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This project will be coordinated by Prof. Jean-Yves Blay, Director of the Léon Bérard comprehensive cancer center, and will consist in collaboration with NETRIS Pharma and Deeplink Medical (i) in performing a clinical POC exploring the netrin-1 mAb in combination with anti-cancer drugs and ICPI in gynecological cancers, renowned for their poor prognosis in advanced stages and for the lack of efficient systemic therapies. Additional aims include (ii) improving general knowledge on DRs in the biology of human cancers in vivoand the associated MoA of interfering with netrin-1/DR interactions, as well as (iii) to perform an ambitious ancillary/translational program to identify biomarkers of efficacy for each netrin-1 mAb/combination treatment.